Latest News and Press Releases

Completed Phase 2 study of NYX-2925 in painful DPN -- did not meet primary endpoint, but NYX-2925 demonstrated robust analgesic activity in a large and mechanistically relevant patient sub-group ...

EVANSTON, Ill., March 14, 2019 (GLOBE NEWSWIRE) -- Aptinyx Inc. (NASDAQ: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous...

EVANSTON, Ill., March 06, 2019 (GLOBE NEWSWIRE) -- Aptinyx Inc. (NASDAQ: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous...

EVANSTON, Ill., Feb. 22, 2019 (GLOBE NEWSWIRE) -- Aptinyx Inc. (NASDAQ: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous...

Favorable safety and tolerability, linear pharmacokinetics, and ample CNS exposure of NYX-783 observed in Phase 1 Phase 2 data anticipated 1H 2020 EVANSTON, Ill., Feb. 19, 2019 (GLOBE NEWSWIRE) --...

NYX-2925 did not achieve statistically significant separation from placebo on primary endpoint Meaningful improvements on pain and other endpoints observed in subjects receiving 50 mg dose and in...

EVANSTON, Ill., Jan. 02, 2019 (GLOBE NEWSWIRE) -- Aptinyx Inc. (NASDAQ: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and...

EVANSTON, Ill., Dec. 11, 2018 (GLOBE NEWSWIRE) -- Aptinyx Inc. (NASDAQ: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous...

EVANSTON, Ill., Dec. 05, 2018 (GLOBE NEWSWIRE) -- Aptinyx Inc. (NASDAQ: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and...

Achieved statistical significance on primary imaging-based endpoint, changes in markers of central pain processing, in 11 subjects Observed corresponding trends of improvement on multiple secondary...